



	DAY 1 – March 31 st
12:00PM-12:20PM	LEO Innovation Lab: how a new clinical paradigm was created within a 110-year old company
	 How an open-minded approach to evidence enabled the identification of new subtypes of diseases through RWD
	 A guide to successful remote clinical trials in dermatology and how this was done in an Innovation Lab, separate to the mothership
	 Simplicity is key: avoid complexity on the most complex treatments and ensure your trials don't add to the EHR burden through careful management Rasmus Hogreffe, Head of Virtual Clinical Trials, LEO Innovation Lab
12:20PM–1:50PM EXHIBITION HALL	LUNCH, NETWORKING SESSION AND INTERACTIVE SOLUTION ZONE
1:55PM-2:15PM	Patient involvement from the beginning, not the endpoint
	• How to ensure the patient perspective is always the driver, not the follower, despite the increasing
	prioritization of technological innovation
	 prioritization of technological innovation Identify the gaps in your understanding that you need to fill in order to ensure you have identified stage-gate specific goals that need to be informed by the patient perspective
	 Identify the gaps in your understanding that you need to fill in order to ensure you have identified stage-gate specific goals that need to be informed by





2:35PM-2:55PM	Patient-centric trials are digital trials
	 Use technology to create patient-preferred trials – the trials patients would choose. Integrate new processes to modernise the delivery of development Raise your status with patient community with more ambitious endpoints, aligned goals and a new Standard of Care Sebastian Stratmann, Senior Manager, Clinical Innovation, Merck
4:05PM-4:35PM EXHIBITION HALL	COFFEE BREAK, NETWORKING SESSIONS AND INTERACTIVE
4:35PM-4:55PM	 How to create virtual trial participants Understand the rationale and criteria for building virtual trial cohorts and compensate for lack of participant data A journey through Ipsen's process in building evidence with translational approaches, mixing RWE and clinical data, adding genomics, metabolomics and validating with the FDA Use this aggregated information and high-quality algorithms to create predictions and best target identification Stephane Orssaud, R&D Biometry Innovation Director, Ipsen





4:55PM-5:05PM	 How to lower costs and speed up clinical studies with structured clinical data, electronic patient files and collaborative marketplaces Learn current solutions to speeding up clinical trials and lowering costs in study set-up, execution and collaboration Discover how pharma companies can find more hospitals and recruit patients more quickly with a marketplace for clinical studies Understand how pharma companies can utilize FHIR based structured clinical data and electronic patient files to have live data in their studies
5:15 – 5:55PM	Panel: IMI Trials@Home: Reshaping remote decentralised clinical trials in Europe
	 How to analyse previous centralised/RDC/hybrid trials and develop best-practice protocols to enable a pan-EU pilot
	 Ensure smart, complaint roll-out of RDCT's by forging strong partnerships with HCPs, participants, regulators and other relevant stakeholders
	 Scanning, characterizing available technologies to support RDCTs and applying design thinking processes to create a robust, end-to-end technology package
	Kai Langel, Director, R&D Operations Innovation, Janssen
	Karl-Ludwig Radek, Associate Director, Strategic Account Lead, Global Clinical Operations Germany & Switzerland, Janssen
	Mira Zuidgeest, Assistant Professor, UMC Utrecht





٦

5:55PM-7:25PM EXHIBITION HALL	NETWORKING DRINKS RECEPTION AND INTERACTIVE SOLUTION ZONE
SIGN-UP FOR FREE FOR THIS	CONFERENCE. (FOR BIO AND PHARMA ONLY)
Contact Izzy Gladst	one igladstone@eyeforpharma.com
	DAY 2
6:45AM-7:30AM	eyeforpharma morning run.
	Start your day right and join the eyeforpharma team for a 5k run along Barcelona's beautiful coastline. All levels welcome. Meet at the AC Hotel reception for a 6.45 departure.
9:05AM–9:25AM	Say yes! Overcome perceived risks for new types of trial with unproven ROI
	 Feel the fear and do it anyway: How to determine an appropriate risk tolerance for pursuing unmet needs and betting on approval
	 Rework andomizednal responsibilities to break deadlocks, empower and support Clin Ops, and ensure trials are reimagined in a futureproof manner
	Mohammed Ali, Global Head Digital Development, Global Clinical Operations, Boehringer Ingelheim
	Bert Hartog, Senior Director, Clinical Innovation, Janssen
9:45AM–10:25AM	Panel: The new clinical ecosystem – who will be disrupted, who will be displaced?
	 Gain market maturity by comprehending today's spectrum of different approaches – from centralized Pis to virtual and remote networks. An objective perspective on the landscape of approaches and where they're headed





	 Why new marketplaces and automation could disrupt CROs whilst new data, could disrupt pharma development organizations How technology can disrupt the fundamental nature of trial participation for patients and likely pathways to progression Milind Kamkolkar, Chief Digital Officer, Cellarity Michelle Shogren, Director of Innovation – Pharma R&D Clinical Operations, Bayer
10:25AM–11:05AM	COFFEE BREAK, NETWORKING SESSIONS AND INTERACTIVE
EXHIBITION HALL	SOLUTION ZONE
11:05AM-11:30AM	 Build a collaborative development framework for novel digital endpoints To put the patient at the centre, determine how to define meaningful novel digital endpoints Leverage existing guidance and processes and account for technical complexity in endpoint development How a collaborative business model enables you to fast-track development and improve reliability An assessment of fit-for-purpose technology that enables quick adoption without losing flexibility Kai Langel, Director, R&D Operations Innovation, Janssen
1:00PM-2:00PM	LUNCH, NETWORKING SESSION AND INTERACTIVE
EXHIBITION HALL	SOLUTIONS ZONE





2:00PM-2:20PM	Digital recruitment with depth – how Novartis will increase trial participation
	 An enhanced approach to trial awareness and recruitment which combines broad channels/materials with specific identification of suitable candidates
	 Detaching physician attachment from eligibility – enabling through technology
	 How a multichannel approach can be used to increase awareness and also understand patient profiles. Two-way use of data to enable patent centric trials
	Sam Hariry, Head of Clinical Strategy & Operations, Novartis
2:20PM-2:40PM	Accessing meaningful subject data and clinical insights throughout the clinical trial process
	 Discover how to obtain critical insights into real- time engagement and why they can be the key difference between staying in treatment and discontinuation Rich Christie, Chief Development Officer, AiCure
2:40PM-3:00PM	Build a global digital support network that enables full rollout in multiple territories
	 Find technology providers who can develop and distribute medicines, IoT-type devices, sensors, variables into people's homes in a global setting Build a coalition of partners that ensure your trials deliver effectiveness in new regions Bert Hartog, Senior Director, Clinical Innovation, Janssen
2.2004 4.00014	
3:20PM-4:00PM EXHIBITIN HALL	COFFEE BREAK, NETWORKING SESSIONS AND INTERACTIVE SOLUTION ZONE





4:00PM-4:20PM	Interoperability – both technology and people – as the greatest win for patient care
	 Stop paralyzing your research – find ways to reduce the interoperability burden from the outset and get closer to the universal HER
	• Trust as the key currency for building an alliance for data sharing and efficient coalition between multiple institutions
	 How to work with regulators – understand the FDA/EMA mindset, build alliances and secure acceptance for your innovations
	Joy Bhosai, Chief of Digital Health & Strategy, Duke University
4:40PM-5:00PM	End to end clinical trials using patient records: run andomized trials entirely based on real world data
	 Hear how the CPRD are combing PRO & HER to assess clinical effectiveness purely from RWD sets Janet Valentine, Director of the CPRD, CPRD
5:00PM-5:20PM	Merging man and machine: Unleash the potential of data to empower patients
	 Recruit patient cohorts with easily accessible technology and meet them in the most convenient place possible – their home Improve both quality and breadth of data generated through PROs by exploiting trending wearable technology
	Celine Ulmann, Head of Digital Innovation R&D, Almirall





In The Exhibition at eyeforpharma Barcelona 2020

5:20PM-5:40PM	The Clinical Entrepreneur: how agility will be a necessity for successful digitization of the trial
	 Examples of Lundbeck's efforts to rewrite clinical planning & execution through a faster, iterative, learning model
	 Man vs machine – understand how to balance resources in a smarter way
	• A fresh perspective on the steps required to get your trial from idea to infinity
	Mads Dalsgaard, Senior Vice President, Head of Experimental Medicine & Clinical Development, Lundbeck
5:40PM-6:40PM EXHIBITION HALL	NETWORKING DRINKS RECEPTION IN THE EXHIBITION HALL
6:00PM–7:50PM HILTON DIAGONAL MAR	THE PHARMA NETWORKING PARTY – LOCATED AT THE NEWLY RENOVATED ROOFTOP PURO BEACH BAR AT THE HILTON DIAGOINAL MAR

SIGN-UP FOR FREE FOR THIS CONFERENCE. (FOR BIO AND PHARMA ONLY)

Contact Izzy Gladstone igladstone@eyeforpharma.com